Craig-Hallum Initiates Coverage On Lifecore Biomedical with Buy Rating, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum has initiated coverage on Lifecore Biomedical (NASDAQ:LFCR) with a Buy rating and set a price target of $8.
September 05, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Craig-Hallum has initiated coverage on Lifecore Biomedical with a Buy rating and a price target of $8, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target by Craig-Hallum suggests a positive sentiment towards Lifecore Biomedical. This is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100